ETF Performance Analysis: The Schwab U.S. Large-Cap Value ETF (SCHV) has an implied analyst target price of $32.37, indicating an 11.27% upside from its recent trading price of $29.09.
Notable Holdings with Upside: Key underlying holdings of SCHV, such as Jazz Pharmaceuticals (JAZZ), Corplay Inc (CPAY), and Masimo Corp (MASI), show significant potential upside based on analyst target prices, with JAZZ at 34.91% higher, CPAY at 32.98%, and MASI at 27.40%.
Analyst Target Justification: The article raises questions about whether analysts' target prices are justified or overly optimistic, suggesting that high targets could lead to future downgrades if they do not align with market realities.
Investor Research Recommendation: Investors are encouraged to conduct further research to assess the validity of analyst targets in light of recent company and industry developments.
Wall Street analysts forecast MASI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MASI is 188.40 USD with a low forecast of 162.00 USD and a high forecast of 210.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Analyst Rating
Wall Street analysts forecast MASI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MASI is 188.40 USD with a low forecast of 162.00 USD and a high forecast of 210.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Buy
2 Hold
0 Sell
Moderate Buy
Current: 143.930
Low
162.00
Averages
188.40
High
210.00
Current: 143.930
Low
162.00
Averages
188.40
High
210.00
Wells Fargo
Overweight
maintain
$187 -> $190
2025-12-05
Reason
Wells Fargo
Price Target
$187 -> $190
AI Analysis
2025-12-05
maintain
Overweight
Reason
Wells Fargo raised the firm's price target on Masimo to $190 from $187 and keeps an Overweight rating on the shares. The firm says the company's Investor Day highlighted confidence in multi-year growth trajectory. Wells also notes that 7%-10% revenue CAGR through 2028, with new products is expected to drive double digits growth post-2028.
BTIG
Buy
maintain
$198 -> $200
2025-12-04
Reason
BTIG
Price Target
$198 -> $200
2025-12-04
maintain
Buy
Reason
BTIG raised the firm's price target on Masimo to $200 from $198 and keeps a Buy rating on the shares after the company's Investor Day presentation. The firm is positive on the company's potential to be one of the most consistent performers in MedTech over the coming years, the analyst tells investors in a research note. BTIG adds that it likes that the company will continue to invest in next-gen sensors and monitors in a market that has seen minimal product innovation from competitors and believes it will allow the company to achieve sustainable high single digit growth during and beyond the Long Range Plan.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for MASI
Unlock Now
BofA
Neutral
initiated
$162
2025-11-17
Reason
BofA
Price Target
$162
2025-11-17
initiated
Neutral
Reason
BofA initiated coverage of Masimo with a Neutral rating and $162 price target.
Piper Sandler
Jason Bednar
Overweight
maintain
$200 -> $210
2025-08-06
Reason
Piper Sandler
Jason Bednar
Price Target
$200 -> $210
2025-08-06
maintain
Overweight
Reason
Piper Sandler analyst Jason Bednar raised the firm's price target on Masimo to $210 from $200 and keeps an Overweight rating on the shares. The firm notes the company announced Q2 revenue of $370M/+7% cc in line with Street's $369M, a minor victory considering perceived risk tied to the cybersecurity incident that negatively affected order fulfillment during May. The only question being circulated ties to incremental contracting being down year-over-year, but Piper finds it hard to give this too much negative weight when considering contract backlog still expanded nicely year-over-year.
About MASI
Masimo Corporation is a global medical technology company that develops and produces a wide range of monitoring technologies, including measurements, sensors, patient monitors, automation and connectivity solutions. The Company’s healthcare products and patient monitoring solutions generally incorporate a monitor or circuit board, proprietary single-patient use or reusable sensors, software and/or cables. It primarily sells its healthcare products to hospitals, emergency medical service providers, home care providers, physician offices, veterinarians, long-term care facilities. Its measurement technologies include Measure-through Motion and Low Perfusion pulse oximetry, known as Masimo Signal Extraction Technology (SET) pulse oximetry, and advanced rainbow Pulse CO-Oximetry parameters such as noninvasive hemoglobin (SpHb), alongside many other modalities, including brain function monitoring, hemodynamic monitoring, regional oximetry, capnography and gas monitoring, and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
